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Keratoacanthoma (KA) is a benign epidermal tumor, charac-
terized by rapid and abundant growth, a tendency toward 
spontaneous regression and histopathologic similarity to 
squamous cell carcinoma (SCC). Because KA can be easily 
misdiagnosed as SCC, surgery is considered the treatment of 
choice. Recently, regression of KAs following application of 
5% imiquimod cream (Aldara
Ⓡ) has been reported. We 
present 4 cases of KA treated with topical imiquimod, 
applied 3 to 4 times a week. Obvious improvement was 
observed after 4 to 6 weeks of application and the lesions 
were almost cleared leaving scars after 9 to 11 weeks. These 
results show that topical imiquimod can be an effective 
option for the conservative management of KA as previously 
reported. We also suggest that lesions treated with imi-
quimod cream should be considered for biopsy to judge 
histopathological remission after 5 to 8 weeks of application 
to shorten the duration of the treatment. (Ann Dermatol 23(3) 
357∼361, 2011)
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INTRODUCTION
Keratoacanthoma (KA) is a benign epidermal tumor, 
characterized by rapid and abundant growth, a tendency 
toward spontaneous regression, and histopathologic simi-
larity to squamous cell carcinoma (SCC). Since the first 
case of solitary KA was reported in 1889, there have been 
debates on whether KA is benign or not, because of its 
histological resemblance to SCC
1. In typical cases, the 
policy of watchful waiting may be adopted, because KA 
usually regresses spontaneously. However, because of the 
frequent misdiagnosis of SCC as KA and the possibility of 
destruction of cosmetically significant organs, treatments 
have usually been recommended. Therapeutic options 
include complete excision, radiation therapy, intralesional 
injection of chemotherapeutic agents, oral retinoids and 
photodynamic therapy
1. Recently, there are a few reports 
of successful treatment of KA by applying 5% imiquimod 
cream (imidazolquinoline, Aldara
Ⓡ) .  H e r e  w e  p r e s e n t  4  
cases of KA successfully treated with topical imiquimod.
CASE REPORT 
Case 1
An 82-year-old Korean man presented with a well- 
demarcated round nodule on the left shoulder. The lesion 
appeared 1 month earlier. The physical examination 
revealed a well-circumscribed, 1.2 cm round nodule with 
a central ulcer on his left shoulder (Fig. 1A). He was 
healthy but a light smoker. After histopathological evalua-
tion, the diagnosis of KA was confirmed. After 6 weeks of 
treatment with the imiquimod cream three times per 
week, the lesion significantly regressed. After 11 weeks, it 
was completely cleared (Fig. 1B). There were neither scars 
nor recurrence after 4 years follow-up. HC Jeon, et al
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Fig. 1. (A) The lesion of case 1 on 
the left shoulder before therapy. (B) 
The lesion regressed completely after
11 weeks.
Fig. 2. (A) The lesion of case 2 before
therapy. (B) The lesion regressed 
completely after 10 weeks.
Case 2
A 62-year-old Korean woman presented with a walnut- 
sized black-crusted crateriform tumor on her nose that had 
been present for a few months (Fig. 2A). The lesion was 
previously treated with carbon dioxide laser, but it 
recurred. She was systemically well and no enlarged 
lymph node was found. After histopathological study, the 
diagnosis of KA was confirmed. We treated her with 
applying imiquimod cream 3 times a week. After 6 weeks, 
the skin lesion remarkably decreased in size. After 10 
weeks, the lesion was completely cleared leaving a scar 
(Fig. 2B). The application was maintained for another 2 
weeks. She remained asymptomatic over a 10-month Treatment of KA with 5% Imiquimod Cream and Review
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Fig. 3. (A) The lesion of case 3 on the right cheek before therapy. (B) The lesion regressed completely after 13 weeks.
Fig. 4. (A) The lesion of case 4 before
therapy. (B) The lesion regressed 
completely after 12 weeks.
follow-up.
Case 3
A 64-year-old man came to our clinic complaining of a 
rapidly growing firm round erythematous 1.2 cm sized 
nodule with a keratin plug on his right cheek (Fig. 3A), 
which had appeared 3 weeks ago. He had hyperchole-
sterolemia and benign prostatic hypertrophy. We dia-
gnosed it as KA clinically from the short history and the 
typical picture, and imiquimod cream was applied 3 times 
a week. Inflammatory reaction appeared after 2 weeks of 
application, but we encouraged him to continue the treat-
ment. The tumor remarkably regressed after 5 weeks. After 
9 weeks, the lesion was completely cleared leaving a scar. 
The treatment was maintained for another 4 weeks (Fig. 
3B). No new lesions were seen at 1-year follow-up.
Case 4
An 85-year-old man presented with a well-circumscribed 
firm dome-shaped ulcerative nodule of 1.5 cm diameter 
on his right cheek (Fig. 4A). The lesion first appeared 3 
months earlier and was treated 2 times with intralesional 
methotrexate injection, but relapsed. Histopathological 
examination suggested KA, but a highly differentiated SCC 
could not be completely excluded. We treated him with 
the imiquimod cream application 3 to 4 times a week. HC Jeon, et al
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Table 1. Previously reported cases of keratoacanthoma treated with imiquimod cream. The average duration to obvious improvement
was 5.0±1.8 weeks, and that to complete remission was 7.4±2.2 weeks
Author Sex/Age (yrs) Size (cm) Location
Duration (weeks)
Frequency of
application Tumor Obvious
improvement
Complete
remission
  Dendorfer et al.
11 M/64 0.7 Nose  5 (*) 2 11 (*) 1/2d
F/63 1 Nose  6 (*) 4  4 (*) 1/2d
F/47 0.8 Upper lip  4 (*) 6  6 1/2d
M/82 0.7 Nose  1 6  6 1/2d
  Bhatia
12 F/ 3.2 Rt. cheek   - -  6 1/2d→1/d
  Di Lernia et al.
13 F/54 1 Lt. cheek  3 (*) 7  8 3/w
F/63 0.9 Lt. cheek   - (*) 7  8 5/w
  Kim et al.
14 M/35 1.5 Nose  4 (*) -  5 1/d→1/2d
  K o  e t  a l .
15 M/35 1.5 Nose  4 (*) 2  5 1/d→1/2d
F/67 0.4 Lt. cheek  3 (*) -  5 (*) 1/d→1/2d
  Calista and Morri
16 M/73 - Nose  8 (*) -  8 1/d (10 d)→3/w
F/77 1.8 Nose  1 (*) -  8 1/d (10 d)→3/w
M/76 7 Lt. cheek  3 (*) -  8 1/d (10 d)→3/w
  Paternò et al.
17 M/53 - Lt. thumb 36 (*) -  6 (*) 5/w
  Our cases M/82 1.2 Lt. shoulder  4 (*) 6 11 3/w
F/62 2 Nose  8 (*) 6 10 3/w
M/64 1.2 Rt. cheek  3 5  9 3/w
M/85 1.5 Rt. cheek 12 (*) 4 10 3/w→4/w
*Confirmed by biopsy (initial diagnosis, or complete remission)
Obvious improvement was observed after 4 weeks. After 
10 weeks, the lesion was completely cleared leaving a 
scar. The treatment was continued for another 2 weeks 
(Fig. 4B) and no recurrence was observed over a period of 
6 months.
DISCUSSION 
Solitary KA, the most common subtype of KA, is a rapidly 
growing tumor that reaches 10 to 25 mm in diameter in 6 
to 8 weeks
2,3. It develops into a firm dome-shaped flesh- 
colored tumor with a central keratin-filled crater. After 
rapid proliferation, a mature KA undergoes regression in 4 
to 6 weeks, leaving an atrophic and hypopigmented 
scar
4,5. This process from proliferation to regression 
usually takes about 4 to 9 months, but there are some 
persistent cases which last for over 1 year
1.
KA is regarded as a tumor which is derived from follicular 
infundibulum
6. This explains its common involvement to 
the hair-bearing areas, like the face, neck, and hands
1. 
However, keratin analyses of KA show the characteristics 
of both follicular differentiation and SCC
7. In addition, KA 
usually demonstrated a histopathologic pattern often 
resembling that of a typical SCC, and there is no criterion 
to distinguish KA from SCC with sufficient sensitivity and 
specificity
7. Furthermore, local destructions following 
rapid growth and metastases to other organs were 
observed in a few cases, although they had a tendency to 
spontaneously regress. In addition, treatment minimizes 
scarring which helps better cosmetic results. Therefore, 
treatment is recommended in most cases.
Complete surgical excision is the treatment of choice, but 
complete excision can be too destructive and cosmetically 
or functionally unacceptable for tumors on cosmetically 
important sites. There are many other treatment options of 
KA with various outcomes, such as cryotherapy, radio-
therapy, intralesional injection of chemotherapeutic agent 
or interferon alpha, and topical 5-fluorouracil
8 with a 
variable success rate.
These treatment options have some limitations. Surgical 
interventions (laser-, electro- and cryo-surgery) may also 
lead to substantial defects with functional or cosmetic 
morbidity, and may not allow the histopathologic confir-
mation of the clinical diagnosis. Radiotherapy is an effec-
tive treatment of KA
9, but it is inappropriate for younger 
patients and is inconvenient because of the need for 
multiple visits to the hospital. Intralesional injection of 
chemotherapeutic agent has also proved therapeutically 
successful
10. However, intralesional methotrexate therapy 
can have adverse events like pancytopenia, so a complete 
blood cell count should be considered to monitor for 
potential cytopenia. Also, intralesional 5-fluorouracil requires 
anesthesia for local pain control, with injections per-
formed at consecutive week intervals
10.
Recently, there are some reports of successful treatment 
with topical imiquimod (Table 1)
11-17, a widely used Treatment of KA with 5% Imiquimod Cream and Review
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topical immunomodulator in the group of toll-like re-
ceptor 7 and 8 agonist. Four to 11 weeks of application 
were required for the treatment, and sometimes adverse 
events which depended on the inflammation resulting 
from the immunological reaction, such as burning sensa-
tion, erythema and erosions occurred. In spite of these 
inconveniences, KA can be treated with topical imi-
quimod, because of lower invasiveness, non-inferiority in 
functional or cosmetic outcome and recent cases of suc-
cessful treatment with topical imiquimod. 
We analyzed 18 cases of KA treated with topical imi-
quimod (previously reported cases and ours). Data were 
statistically analyzed with a Mann-Whitney test using the 
SPSS version 17.0 statistical package (SPSS, Chicago, IL, 
USA). There were no statistically significant differences 
between previously reported cases and ours, except in the 
period of time to gain complete remission (p=0.005). The 
medians of the duration to complete remission were 6 
weeks in 14 previously reported cases (range of 4 to 11 
weeks), and 10 weeks in our 4 cases (range of 9 to 11 
weeks).
Frequent application of imiquimod at the initial treatment 
was reported to induce a prompt regression of KA
15. 
However, the analysis of previously reported cases 
showed no statistically significant difference in the 
duration to remission between cases applied once per day 
(median: 6.5 weeks; range of 5 to 8 weeks) and less than 
once per day (median: 6 weeks; range of 4 to 11 weeks; 
p=0.755). Similarly, the duration to complete remission 
was not related to age, size and the duration of KA. 
The longer duration to complete remission in our cases 
may be caused by lack of histopathologic confirmation of 
remission, not by the frequency of application of initiation 
therapy. The duration required for clinical complete remi-
ssion may be longer than that of histopathological remi-
ssion, because the inflammation induced by imiquimod 
can make it difficult for clinicians to judge clinical cure. 
Mature KA undergoes regression in 6 weeks and topical 
imiquimod can promote the regression of KAs
13. Further-
more, in previous cases of KA treated with imiquimod 
(Table 1), the average duration to obvious improvement 
was 5 weeks, and that to complete remission was 7.4 
weeks. Therefore, after 5 to 8 week application, the 
lesions should be considered for biopsy to judge histo-
pathological cure, if serial biopsies are not acceptable 
cosmetically.
In conclusion, topical imiquimod can be an effective 
option for the non-operative management of KA. For 
shortening the duration of the treatment, the histopatho-
logical confirmation of complete remission should be 
suggested. Further study is needed to investigate effective 
application frequency and duration of maintenance.
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